BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 466 filers reported holding BIO-TECHNE CORP in Q1 2021. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,666,286 | -10.6% | 24,479 | +7.2% | 0.01% | -12.5% |
| Q2 2023 | $1,864,021 | +12.8% | 22,835 | +2.5% | 0.01% | 0.0% |
| Q1 2023 | $1,652,360 | -10.5% | 22,272 | 0.0% | 0.01% | -20.0% |
| Q4 2022 | $1,845,903 | +16.4% | 22,272 | +298.9% | 0.01% | +11.1% |
| Q3 2022 | $1,586,000 | -8.8% | 5,583 | +11.3% | 0.01% | -10.0% |
| Q2 2022 | $1,739,000 | -52.7% | 5,018 | -40.9% | 0.01% | -44.4% |
| Q1 2022 | $3,680,000 | -16.3% | 8,497 | 0.0% | 0.02% | -14.3% |
| Q4 2021 | $4,396,000 | -0.2% | 8,497 | -6.6% | 0.02% | -12.5% |
| Q3 2021 | $4,406,000 | +8.9% | 9,093 | +1.2% | 0.02% | +9.1% |
| Q2 2021 | $4,045,000 | +170.7% | 8,984 | +129.7% | 0.02% | +144.4% |
| Q1 2021 | $1,494,000 | +2.4% | 3,912 | -14.9% | 0.01% | 0.0% |
| Q4 2020 | $1,459,000 | +34.3% | 4,596 | +4.9% | 0.01% | +12.5% |
| Q3 2020 | $1,086,000 | -1.5% | 4,382 | +4.9% | 0.01% | -20.0% |
| Q2 2020 | $1,103,000 | +77.9% | 4,178 | +27.8% | 0.01% | +66.7% |
| Q1 2020 | $620,000 | +7.6% | 3,270 | +24.7% | 0.01% | +50.0% |
| Q4 2019 | $576,000 | +27.2% | 2,622 | +13.4% | 0.00% | 0.0% |
| Q3 2019 | $453,000 | -6.0% | 2,313 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $482,000 | +10.0% | 2,313 | +4.8% | 0.00% | 0.0% |
| Q1 2019 | $438,000 | +15.9% | 2,207 | -15.4% | 0.00% | 0.0% |
| Q4 2018 | $378,000 | -21.9% | 2,609 | +10.0% | 0.00% | 0.0% |
| Q3 2018 | $484,000 | +45.8% | 2,371 | +5.6% | 0.00% | +33.3% |
| Q2 2018 | $332,000 | -17.4% | 2,246 | -15.6% | 0.00% | -25.0% |
| Q1 2018 | $402,000 | +50.0% | 2,662 | +28.7% | 0.00% | +100.0% |
| Q4 2017 | $268,000 | +52.3% | 2,069 | +42.1% | 0.00% | 0.0% |
| Q3 2017 | $176,000 | +2.9% | 1,456 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $171,000 | +30.5% | 1,456 | +12.6% | 0.00% | +100.0% |
| Q1 2017 | $131,000 | -1.5% | 1,293 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $133,000 | -6.3% | 1,293 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $142,000 | +10.1% | 1,293 | +13.4% | 0.00% | -50.0% |
| Q2 2016 | $129,000 | +19.4% | 1,140 | 0.0% | 0.00% | +100.0% |
| Q1 2016 | $108,000 | +4.9% | 1,140 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $103,000 | +128.9% | 1,140 | +135.1% | 0.00% | 0.0% |
| Q3 2015 | $45,000 | +150.0% | 485 | +159.4% | 0.00% | – |
| Q2 2015 | $18,000 | -5.3% | 187 | 0.0% | 0.00% | – |
| Q1 2015 | $19,000 | – | 187 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |